MUC5B, TERT, and Telomeropathies in Idiopathic Pulmonary Fibrosis

MUC5B, TERT, and Telomeropathies define the dual genetic architecture of idiopathic pulmonary fibrosis (IPF), a progressive and lethal interstitial lung disease characterized histopathologically by usual interstitial pneumonia (UIP), subpleural honeycombing, fibroblastic foci, and a median untreated survival of 3 to 5 years from diagnosis. For decades, IPF was attributed to uncharacterized environmental alveolar injury; however, family linkage and genome-wide association studies (GWAS) revealed that >35% to 45% of the total heritable liability of sporadic and familial pulmonary fibrosis is governed by two biological pathways located predominantly within human subtelomeres: mucociliary clearance proteins in the Chr11p15.5 gel-forming mucin cluster (MUC5B) and telomere-replication enzymes (TERT on subtelomeric Chr5p15.33, TERC, RTEL1 on subtelomeric Chr20q13.33, and PARN).

These two genetic axes converge anatomically at the distal respiratory bronchiole and adjacent alveoli. On the bronchiolar side, the common gain-of-function promoter polymorphism rs35705950 (G>T) upstream of MUC5B drives a 34-fold overexpression of polymeric mucin 5B in distal terminal bronchioles, clogging mucociliary clearance and triggering chronic endoplasmic reticulum (ER) unfolded protein stress. On the alveolar side, germline loss-of-function mutations in TERT, TERC, RTEL1, or PARN accelerate telomere shortening (<10th or <1st age-adjusted percentile) in alveolar type II (AT2) epithelial stem cells. When mucociliary stasis and inhaled micro-injuries demand epithelial regeneration, telomere-exhausted AT2 cells undergo p53/p21 (CDKN1A)-mediated replicative senescence rather than proliferating into gas-exchanging alveolar type I (AT1) cells, secreting a profibrotic senescence-associated secretory phenotype (SASP—TGF-β1, IL-6, CTGF, PAI-1) that drives myofibroblast collagen deposition.

Subtelomeric Organization of Secreted Gel-Forming Mucins

The human secreted gel-forming mucin gene cluster spans ~400 kb on the short-arm subtelomere of chromosome 11p15.5 (immediately telomeric to the imprinted IGF2–H19 domain) in the tandem order:

5′ (Telomere) — MUC6 — MUC2 — MUC5AC — MUC5B — 3′ (Centromere)

Encoded across 49 exons (~39 kb genomic span, 5,762 amino acids, >590 kDa core apomucin monomer before O-glycosylation), MUC5B is the primary viscoelastic gel-forming mucin responsible for baseline mucociliary clearance in human conducting airways and submucosal glands. Structurally, MUC5B contains three N-terminal von Willebrand factor type D (vWD1–vWD3) domains that form intermolecular disulfide-linked dimers in the endoplasmic reticulum (ER), a massive central exon (Exon 31, 10,713 bp in length) encoding proline-, threonine-, and serine-rich (PTS) tandem repeats heavily modified by O-linked oligosaccharides (up to 80% of the mature 2–50 MDa polymer mass), and C-terminal vWD4/cystine-knot domains that assemble into linear disulfide-linked polymers in the acidic trans-Golgi network.

FOXA2 Binding Disruption, XBP1s ER Stress, and the Survival Paradox

In 2011, Seibold, Schwartz, and colleagues discovered that a single guanine-to-thymine transversion located 3 kb upstream of the MUC5B transcription start site (rs35705950 G>T) is the strongest common genetic risk factor for both familial interstitial pneumonia and sporadic IPF:

1. Odds Ratio and Penetrance: Present at a minor allele frequency (MAF) of ~9% to 11% in European populations (but <1%–2% in East Asian and African cohorts, explaining the lower incidence of IPF in those populations), the rs35705950-T allele increases the odds of IPF by OR ≈ 6.8 (95% CI: 5.2–8.9) in G/T heterozygotes and OR ≈ 20.8 (95% CI: 11.4–37.9) in T/T homozygotes—an effect size rivaling APOE ε4 in Alzheimer's disease.
2. Epigenetic Derepression and FOXA2 Displacement: The rs35705950 SNP lies within a conserved distal enhancer element in the 5′ flanking region of MUC5B that undergoes differential DNA methylation and chromatin opening in distal airway secretory cells. The G>T substitution alters a binding motif for the pioneer transcription factor FOXA2 (which normally represses MUC5B in distal bronchioles) while facilitating recruitment of SP1, HOXA9, and the ER-stress transcription factor spliced X-box binding protein 1 (XBP1s).
3. Bronchiolar Honeycomb Cyst Formation and the Prognostic Survival Paradox: In healthy lungs, MUC5B expression is restricted to proximal cartilaginous airways and submucosal glands. In rs35705950-T carriers, MUC5B mRNA is upregulated 34-fold in non-fibrotic lung parenchyma and ectopically expressed throughout terminal and respiratory bronchioles (SCGB3A2⁺/SFTPB⁺ secretory cells). Folding and disulfide-crosslinking such vast quantities of 5,762-aa MUC5B monomers overwhelms the ER chaperone AGR2 and activates the inositol-requiring enzyme 1α (IRE1α)–XBP1s unfolded protein response (UPR), creating a self-amplifying positive feedback loop where XBP1s binds the rs35705950-T enhancer to drive even higher MUC5B transcription. Remarkably, among diagnosed IPF patients, carriers of rs35705950-T display slower annual forced vital capacity (FVC) decline and ~1.5- to 2-year longer median survival than non-carriers (whose disease is more frequently driven by rapid-progression telomerase mutations), and evolutionary analyses indicate that rs35705950-T was maintained in Europeans by positive selection for enhanced innate mucosal defense against respiratory bacterial pathogens.

Subtelomeric TERT and RTEL1 in Telomere Maintenance

While MUC5B rs35705950 drives common sporadic late-onset IPF, whole-exome sequencing of familial pulmonary fibrosis (FPF) kindreds demonstrates that 25% to 35% of familial cases (and ~10% of sporadic cases) harbor rare heterozygous loss-of-function variants in genes governing telomere maintenance:

1. TERT (Telomerase Reverse Transcriptase on Subtelomeric Chr5p15.33): Encodes the 1,132-amino-acid catalytic reverse transcriptase subunit (16 exons, located just 1.25 Mb from the 5p telomere) that uses an internal RNA template to add hexameric 5′-TTAGGG-3′ repeats onto 3′ chromosome ends. Because TERT is located in a subtelomeric chromatin environment subject to telomere position effects (TPE-OLD), heterozygous coding mutations (p.Arg865His, p.Val694Met) cause strict haploinsufficiency, reducing telomerase processivity by ~50% and causing progressive telomere erosion across successive generations (genetic anticipation, where grand-offspring develop bone marrow failure in childhood while grandparents developed IPF at age 60).
2. TERC (Chr3q26.2) and PARN (Chr16p13.12): TERC encodes the 451-nucleotide H/ACA box non-coding RNA scaffold containing the 11-nt template sequence. Nascent TERC transcripts carry aberrant 3′ oligo(A) tails added by the non-canonical polymerase PAPD5 (TENT4B) that target TERC for destruction by the nuclear RNA exosome; poly(A)-specific ribonuclease (PARN) deadenylates and rescues TERC, which is why PARN loss-of-function mutations deplete cellular TERC by >60% (a defect reversible in preclinical models by small-molecule PAPD5 inhibitors).
3. RTEL1 (Regulator of Telomere Elongation Helicase 1 on Subtelomeric Chr20q13.33): Encodes an essential iron-sulfur (4Fe-4S) DEAH-box DNA helicase located at the 20q subtelomere. During S-phase DNA replication, RTEL1 unwinds the lariat-like telomeric T-loop (3′ overhang invasion into duplex TTAGGG DNA) and resolves G-rich G-quadruplex (G4) structures on the lagging-strand template. When RTEL1 is mutated, structure-specific endonucleases (SLX4 complex) cleave stalled T-loops, excising circular telomeric T-circles and causing abrupt telomere truncation.

AT2 Stem-Cell Failure, p53 Activation, and Clinical Harm of Immunosuppression

In the adult human lung, facultative stem-cell renewal of the gas-exchanging alveolar epithelium depends on surfactant-producing alveolar type II (AT2) cells. When telomeres in AT2 cells shorten below a critical threshold (~4–5 kb, triggering uncapping of the shelterin complex: TRF1, TRF2, POT1, TIN2, TPP1, RAP1), exposed chromosome ends are recognized as double-strand DNA breaks by ATM/ATR kinases. This stabilizes p53 (TP53) and upregulates the cyclin-dependent kinase inhibitor p21 (CDKN1A), permanently arresting AT2 proliferation and blocking AT2 → AT1 transdifferentiation while suppressing PGC-1α mitochondrial biogenesis. Senescent AT2 cells secrete TGF-β1, IL-1β, and WNT ligands that recruit CTHRC1⁺ profibrotic fibroblasts, targeted clinically by the antifibrotics pirfenidone (TGF-β modulator), nintedanib (PDGFR/FGFR/VEGFR tyrosine kinase inhibitor), and nerandomilast (BI 1015550, a selective phosphodiesterase-4B PDE4B inhibitor). Crucially, pharmacogenomic analysis of the landmark PANTHER-IPF trial demonstrated that IPF patients with short leukocyte telomeres (<10th percentile) or TERT/RTEL1 mutations suffer markedly increased mortality, hospitalizations, and bone-marrow/infectious toxicity when treated with cytotoxic immunosuppression (prednisone + azathioprine), establishing leukocyte telomere length (Flow-FISH) and MUC5B/TERT genotyping as essential precision-medicine biomarkers.

Why does the MUC5B rs35705950-T variant increase the risk of developing IPF 7- to 20-fold, yet predict slower disease progression after diagnosis?

The rs35705950-T enhancer allele causes 34-fold overexpression of MUC5B in distal respiratory bronchioles, initiating mucociliary stasis, XBP1s-mediated endoplasmic reticulum stress, and honeycombing over many decades (OR ≈ 6.8–20.8). However, once IPF is diagnosed, rs35705950-T carriers have a slower rate of forced vital capacity (FVC) loss and longer survival than G/G non-carriers because G/G IPF cases are heavily enriched for short-telomere (TERT/RTEL1/PARN) stem-cell failure, which drives rapid, diffuse alveolar collapse.

How do mutations in PARN cause short telomeres and pulmonary fibrosis when PARN is an RNA deadenylase rather than a DNA polymerase?

During biogenesis in the nucleus, nascent transcripts of the telomerase RNA template (TERC) are oligoadenylated at their 3′ end by the polymerase PAPD5, which marks TERC for rapid degradation by the nuclear RNA exosome. PARN trims these 3′ oligo(A) tails to generate mature, stable TERC. Heterozygous loss-of-function mutations in PARN allow TERC degradation, depleting functional telomerase enzyme complexes and shortening alveolar stem-cell telomeres.

Why is immunosuppressive therapy (such as azathioprine and prednisone) contraindicated in IPF patients with short telomeres?

In the PANTHER-IPF clinical trial and subsequent pharmacogenomic studies, IPF patients with leukocyte telomere lengths below the 10th percentile (or pathogenic TERT/TERC/RTEL1/PARN variants) experienced a 3-fold surge in mortality and severe adverse events when exposed to azathioprine and prednisone. Because their hematopoietic and epithelial stem cells already suffer from telomere-driven replicative exhaustion, antimetabolite immunosuppressants trigger bone marrow aplasia, Opportunistic pulmonary infections, and accelerated alveolar senescence.

1. Seibold, M. A., Wise, A. L., Speer, M. C., et al. (2011). "A common MUC5B promoter polymorphism and pulmonary fibrosis." New England Journal of Medicine, 364(16), 1503–1512. https://doi.org/10.1056/NEJMoa1013660
2. Armanios, M. Y., Chen, J. J., Cogan, J. D., et al. (2007). "Telomerase mutations in families with idiopathic pulmonary fibrosis." New England Journal of Medicine, 356(13), 1317–1326. https://doi.org/10.1056/NEJMoa066157
3. Stuart, B. D., Choi, J., Zaidi, S., et al. (2015). "Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening." Nature Genetics, 47(5), 512–517. https://doi.org/10.1038/ng.3278
4. Chen, G., Ribeiro, C. M. P., Sun, L., et al. (2019). "XBP1S regulates MUC5B in a promoter variant-dependent pathway in idiopathic pulmonary fibrosis." American Journal of Respiratory and Critical Care Medicine, 200(2), 220–234. https://doi.org/10.1164/rccm.201809-1672OC